VLT-TIR

A dual GIP/GLP-1 receptor agonist peptide that appears in metabolic and incretin research literature.

VLT-TIR is a synthetic peptide described in the literature as a dual agonist at the GIP and GLP-1 receptors. As a research material it is handled as a defined incretin-based peptide and has been the subject of research examining dual receptor engagement and metabolic signaling. This page is background about the molecule and is not medical guidance or intended for human use.

Classification and structure

VLT-TIR is classified as a peptide, structurally a single acylated chain engineered to interact with two distinct incretin receptors. Its sequence draws on the GIP peptide framework with modifications that extend its circulating half-life in study systems. It is supplied strictly as a research material.

Areas of research

In the published literature, vlt-tir appears most often in the following research areas.

• Dual incretin receptor signaling — Investigated in models examining simultaneous GIP and GLP-1 receptor engagement.
• Glucoregulatory research — Appears in the literature on glucose-handling and metabolic pathway models.
• Energy-balance models — Studied in research examining metabolic and energy-balance signaling.

As always in this library, describing a compound as “studied in” an area is a statement about where scientific attention has gone — not a claim that it produces any result in humans or animals.

Handling and verification

Lyophilized vlt-tir is generally kept cold and dry until reconstitution in the laboratory setting. Every in-stock lot ships with a third-party certificate of analysis that can be verified by its lot number.